Behcet's disease--ophthalmological and general aspects: Part 2: Therapy (Q44524653)

3 December 2017

title

Behcet's disease--ophthalmological and general aspects: Part 2: Therapy (English)

1 reference

3 December 2017

0 references

U Pleyer

1

1 reference

3 December 2017

D Hazirolan

series ordinal

2

1 reference

3 December 2017

S Winterhalter

series ordinal

3

1 reference

3 December 2017

N Stübiger

series ordinal

4

1 reference

3 December 2017

language of work or name

German

0 references

publication date

1 March 2013

1 reference

3 December 2017

1 reference

3 December 2017

volume

110

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

273-284

1 reference

High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Effectiveness of cyclosporin therapy for Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Immunotherapy for Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

A double-blind trial of colchicine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Anti-TNF-α treatment for uveitis. Analysis of the current situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Light on the Horizont: biologicals in Behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Behçet's disease: ocular effects and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

[Behçet's disease - ophthalmological and general aspects part I : etiology, pathogenesis and diagnostics].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00347-012-2780-Z

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

21 January 2018

1 reference

12 December 2020

[Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment]

1 reference

12 December 2020

Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects

1 reference

12 December 2020

Treatment of BehÇet's disease

1 reference

12 December 2020

Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.

1 reference

12 December 2020

Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine

1 reference

12 December 2020

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

10.1007/S00347-012-2780-Z

Identifiers

DOI

1 reference

3 December 2017

1 reference